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background:  The incidence of stent thrombosis (ST) may have declined over the last several years. We studied the temporal change in 
the incidence of ST in the context of continuously improving antiplatelet regimen (AR) and coronary stent (CS) technology.
methods:  We retrospectively examined the percutaneous coronary intervention (PCI) database at our academic center between 2006 and 
2013. Patients (pts) with definite, probable and possible ST within 1 year of index PCI were identified (per academic research consortium 
definition). The AR and characteristics of CS at the time of index PCI were recorded for pts developing ST.
Results:  The study sample included 4460 pts. Of those, 210 pts (4.7%) developed ST (71: definite, 22: probable, 117: possible). Pts with 
ST (compared to without ST) were older (68±13 vs 62±13, p<0.0001); had higher smoking (53% vs 32%, p<0.0001), diabetes (67% vs 
28%, p=0.009), STEMI (43% vs 33%, p=0.005), average stent/patient (1.8±1.0 vs 1.6±0.9, p<0.0001); less drug eluting CS/patient (57% 
vs 68%, p=0.0005) and lower use of prasugrel or ticagrelor (as part of AR) after index PCI (13% vs 22%, p=0.006). Both groups were 
comparable with respect to gender and lesion characteristics. Incidence of stent thrombosis, AR and CS type for pts with ST is described in 
Table 1.
conclusion:  We have noticed a steady decline in the incidence of ST from 2006 to 2013. This trend correlates with an increase in the use 
of prasugrel or ticagrelor as well as an increase in the use of second generation drug eluting stents.
Year
Stent thrombosis
Incidence
% (n*/total pts)
Antiplatelet regimen at the time of 
Stent Thrombosis
(In addition to Aspirin)
Stent type** Type of DES placed during initial PCI in patients presenting with Stent Thrombosis
First generation 
DES**
Second generation DES**
Clopidogrel
% (n)
Prasugrel or 
Ticagrelor
% (n)
BMS
% (n)
DES
% (n)
Taxus
% (n)
Cypher
% (n)
Promus
% (n)
Promus
(Premier/ 
Element)
% (n)
Xience
(V, Expedition)
% (n)
Resolute 
Integrity
% (n)
2006 5.8 % (35/599) 100 (35) 12 (4) 88 (31) 88 (31)
2007 6.3% (32/507) 94 (30) 50 (16) 50 (16) 41 (13) 9 (3)
2008 6.1 % (36/586) 98 (35) 61 (22) 39 (14) 25 (9) 6 (2) 8 (3)
2009 4.7 % (25/534) 96 (24) 4 (1) 52 (13) 48 (12) 20 (5) 28 (7)
2010 4.6 % (24/518) 75 (18) 25(6) 50 (12) 50 (12) 12 (3) 38 (9)
2011 4.6 % (24/518) 63 (15) 33 (8) 50 (12) 50 (12) 8 (2) 42 (10)
2012 3.6 % (22/602) 68 (15) 32 (7) 50 (11) 50 (11) 14 (3) 9 (2) 23 (5) 4 (1)
2013 2.0% (12/596) 66 (8) 34 (4) 17(2) 83 (10) 25 (3) 25 (3) 33 (4)
ST: Stent Thrombosis, DES-Drug Eluting Stent, BMS-Bare Metal Stent, PCI-Percutaneous Coronary Intervention, pts-patients
Aspirin use remained unchanged across the study population from 2006 to 2013.
n* represents patients with stent thrombosis;
** denominator is number of patients with stent thrombosis
Average stent dimension: 3.1(±1.2) x 18(±6.2) mm
Taxus was the predominantly used first generation DES in our cardiac catheterization laboratory.
